Chester County News and Community Website
CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) announced it has finalized its acquisition of Retina Consultants of America (RCA), a major management services organization for retina specialists. The transaction, valued …
Cencora Expands Specialty Leadership with $4.4 Billion Acquisition of Retina Consultants of America Read More CONSHOHOCKEN, PA — Cencora has introduced Accelerate Pharmacy Solutions, a comprehensive portfolio aimed at helping hospitals and health systems enhance operations and improve financial performance.
Cencora Launches Accelerate Pharmacy Solutions to Support Hospitals and Health Systems Read More CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) has reported impressive financial results for its fiscal year 2024 fourth quarter, marking a 14.7% increase in revenue to $79.1 billion. The company …
Cencora Reports Strong Revenue Growth in Fourth Quarter, Announces Strategic Initiatives Read More CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) has announced a definitive agreement to acquire Retina Consultants of America (RCA) from Webster Equity Partners for approximately $4.6 billion. This move aims …
Cencora Announces Strategic Acquisition of Retina Consultants of America Read More CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) has announced the appointment of Francois Mandeville as Executive Vice President of Strategy and M&A, and Pawan Verma as Executive Vice President and …
Cencora Strengthens Leadership with Strategic Appointments Read More CONSHOHOCKEN, PA — Cencora, formerly known as AmerisourceBergen, is advancing pharmacy education with the introduction of two new initiatives aimed at deepening pharmacy residents’ understanding of the pharmacy supply chain and …
Cencora Launches Innovative Pharmacy Education Programs to Enhance Supply Chain Expertise Read More CONSHOHOCKEN, PA — Alcura, a part of Cencora, has received a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) from the Spanish Agency of Medicines and …
Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation Read More CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) reported a robust third quarter for fiscal year 2024, with revenue climbing 10.9% year-over-year to $74.2 billion. The company also raised its full-year …
Cencora Reports Stellar Q3 Results and Upbeat Guidance: A Healthcare Investment to Watch Read More